Canavan Disease Clinical Trials and Treatments

Canavan disease (also called Canavan-Van Bogaert-Bertrand disease) is a rare autosomal recessive leukodystrophy caused by mutations in the ASPA gene encoding aspartoacylase, a key enzyme in brain metabolism. This enzyme normally catalyzes hydrolysis of N-acetylaspartate (NAA) to aspartate and acetate, both critical metabolites in the central nervous system. Loss of enzymatic activity causes massive accumulation of NAA in the brain, with characteristic spongy degeneration of white matter defined by intramyelinic edema and vacuolation.

The most common symptoms of Canavan Disease include Developmental delay and hypotonia in infancy, Loss of developmental milestones, Spasticity developing in second year of life, Seizures, Visual and hearing loss, among others. Canavan Disease affects approximately 1 in 13,500 among Ashkenazi Jews; 1 in 100,000 in general population. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Canavan Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Gene therapy represents a promising new frontier for Canavan disease, with clinical trials now actively recruiting eligible patients and showing encouraging early results. Early treatment before extensive white matter damage and neuronal loss occurs may offer substantially better outcomes and preserved function.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Canavan Disease. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

Canavan Disease is caused by variants in the ASPA gene.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. The condition affects approximately 1 in 13,500 among Ashkenazi Jews; 1 in 100,000 in general population. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Canavan Disease looks at the ASPA gene.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Canavan Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Canavan Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.